Xtent: Drug-Eluting Stent Shows Positive Clinical Results

by Sara Calabro
Med Tech Sentinel



These days, Menlo Park, CA-based Xtent (XTNT) is enjoying being the drug-eluting stent company no one’s heard of. Yesterday the firm announced that it was moving forward with the latest configuration of its Custom NX Drug Eluting Stent system, as the technology has proved successful in Xtent’s ongoing Custom III clinical trial in Europe. And the company noted that its U.S. trial is on track to begin in the second half of 2007.

Xtent is hoping that its Custom NX system’s personalized approach to arterial disease — based on a patient’s individual lesion characteristics, a physician can customize the stent length while inside the affected arteries — will help transform the current environment in which “stent” is practically a dirty word.


Source: OneMedPlace.com



RELATED READING:
- The Never Ending Saga Of Bypasses And Stents
- Boston Scientific Looks To IPO Unit As Concerns About Main Business Linger
- New Class of Drug-Eluted Stents on the Horizon
- Boston Scientific to Market Stents in Europe After U.S. Criticism
- Stent Safety Issues at the FDA....Hogwash

_____________________